The late cell stage cell therapy company, Talaris Therapeutics Inc files for a $100 Million IPO On the 16th of April 2021. However, the date of IPO and the price range of the share is yet to be determined. The company would be trading on NASDAQ global under the proposed trading symbol, TALS.
IPO Details
Talaris Therapeutics Inc filed Form S-1 (Registration Statement ) with the Securities and Exchange Commission on the 16th of April 2021. They have filed a $100 Million IPO with Deloitte & Touche LLP as their Auditor. The lead underwriters include Evercore Group L.L.C, Guggenheim Securities, Morgan Stanley & Co. LLC, and SVB Leerink LLC. Computershare Trust Company is their transfer agent and the underwriter counsel is Cooley LLP. Goodwin Proctor LLP is acting as the company c...
